ABBV/AMGN/CHRS/MNTA—In general, I don't expect formulation patents on Humira such as the one in the USPTO ruling today to be a significant impediment to commercialization of Humira FoBs. They ought to be pretty easy to work around, IMO. (See #msg-118781959 for related discussion.)
Market Data 
Markets 
AI
